CircuLite

CircuLite, Inc. is a medical device company founded in November 2004 by Accelerated Technologies, Inc. (ATI) to develop a pocket circulatory assist device for the treatment of NYHA Class III and early Class IV heart failure patients. Paul Spence, MD, a cardiovascular surgeon, conceived the idea of combining a superficially placed miniature blood pump with endovascularly placed inflow and outflow cannulae.

CircuLite’s mission is to change the treatment model of chronic heart failure patients by commercializing a pocket circulatory assist device that can be endovascularly implanted similar to a pacemaker by the interventional cardiologist. A pocket circulatory assist device will allow the transformation of treatment of heart failure from the acute decompensated hospitalized patient to the chronic, ambulatory patient. The CircuLite technology will provide a new treatment option to approximately two million patients who have no other viable option today.

Intarcia

Intarcia is a biopharmaceutical company that applies a targeted approach to the acquisition, development and commercialization of therapeutic products for use in treating cancer and infectious diseases. Intarcia’s lead programs include a combination therapy for the treatment of hormone dependent breast cancer in postmenopausal women and an implant to deliver omega interferon for the treatment of hepatitis C.

Kadmus Pharmaceuticals

Kadmus is a biopharmaceutical company that exploits endocannabinoid pathways to develop innovative therapeutics. Endocannabinoids are naturally occurring signaling molecules whose functions include regulating pain and body weight. Through licensing activity, development partnerships and internal discovery programs, Kadmus is building a portfolio of compounds with activity against a range of disorders of the central nervous system and metabolic disorders, including neuropathic pain and obesity.

GeminX Biotechnologies

GeminX specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body’s natural ability to destroy injured or damaged cells. GeminX’s lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins. GeminX is also developing small molecules that induce apoptosis in p53-defective cancers.

Calypso Medical Technologies

Calypso Medical is a medical device company that develops innovative technology to target unmet medical needs in radiation therapy. Its introductory technology addresses the need for objective motion management through precise and continuous confirmation of a treatment target's location during radiation therapy.

U-Systems

U-Systems designs, develops, manufactures and markets innovative ultrasound systems and computer-aided detection (CAD) software for medical ultrasound. The Company’s first product is a Full-Field Breast Ultrasound System™ (FFBU™). The FFBU system automatically scans the whole-breast. It presents the results to the physician in a mammogram-like format (Somogram™)—enabling high volume, cost-effective ultrasound imaging.

NuGEN Technologies

NuGEN is focused on the development and commercialization of amplification and detection systems for genomic and proteomic research. NuGEN's proprietary SPIA ™ and Ribo-SPIA ™ amplification and labeling system form the foundation for a wide range of products. The Ovation ™ amplification and labeling system, the company's first product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis.

Optimer Pharmaceuticals

Optimer is focused on the research and development of anti-infective products to treat serious bacterial infections. Optimer’s core drug discovery technologies are licensed from Scripps Research Institute and Memorial Sloan-Kettering Cancer Center. The company has a portfolio of pre-clinical and clinical stage antibiotic compounds. Optimer’s lead product is an antibiotic being developed for the treatment of C. difficile-associated diarrhea (CDAD), the leading cause of institutional enteric infections.

geneticXchange

geneticXchange is a software product company that sells data integration middleware. Their product is a software infrastructure for In Silico discovery that is open and embeddable.

Perlegen Sciences

Perlegen is working to provide safe and effective personalized medicines to the world. The company analyzes millions of unique genetic variations in DNA samples and uses the information to explain and predict the efficacy and adverse effects of prescription drugs. Perlegen also applies this expertise to discovering genetic variants associated with disease for potential new therapeutics and diagnostics. Perlegen is able to bring pharmaceutical products to the market whose clinical development would otherwise have been discontinued.

Zyomyx

Zyomyx is an innovator in the development and commercialization of proprietary protein analysis platforms based on its expertise in biochemical, materials science and microsystem technologies. The company's offerings include product development programs, intellectual property out-licensing, and R&D collaborations. In addition, Zyomyx provides a product line of human and murine cytokine protein assays to customers using a streamlined service model.